BioCryst Downgraded By JPMorgan, Analysts Await 'More Data' By: Benzinga via Benzinga February 09, 2016 at 08:51 AM EST The share price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has plunged 82.53 percent over the past one year, reaching ... Read More >> Related Stocks: Biocryst Pharma Inc